{"formats":[{"name":"JSON","format":"json","url":"\/downloads\/2025\/code-json\/38.2-3407.9_05.json"},{"name":"Plain Text","format":"text","url":"\/downloads\/2025\/code-text\/38.2-3407.9_05.txt"},{"name":"XML","format":"xml","url":"\/downloads\/2025\/code-xml\/38.2-3407.9_05.xml"},{"name":"HTML","format":"html","url":"\/downloads\/2025\/code-html\/38.2-3407.9_05.html"}],"law_id":71499,"edition_id":1,"section_id":71499,"structure_id":12994,"section_number":"38.2-3407.9:05","catch_line":"Step therapy protocols","history":"2019, c. 337.","full_text":"A\n\nAs used in this section:\n\t\t\t“Carrier” means any (i) insurer issuing individual or group accident and sickness insurance policies providing hospital, medical and surgical, or major medical coverage on an expense-incurred basis; (ii) corporation providing individual or group accident and sickness subscription contracts; or (iii) health maintenance organization providing a health care plan for health care services. “Carrier” includes any entity administering a policy or plan providing health insurance coverage to state employees pursuant to § 2.2-2818 but does not include any entity administering a policy or plan providing coverage pursuant to Title XVIII of the Social Security Act, 42 U.S.C. § 1395 et seq. (Medicare); Title XIX of the Social Security Act, 42 U.S.C. § 1396 et seq. (Medicaid); or Title XXI of the Social Security Act, 42 U.S.C. § 1397aa et seq. (CHIP).\n\t\t\t“Clinical practice guideline” means a systematically developed statement to assist decision making by providers about appropriate health care for a specific clinical circumstance or condition.\n\t\t\t“Clinical review criteria” means the written screening procedures, decision abstracts, clinical protocols, and practice guidelines used by a carrier, utilization review organization, or independent review organization to determine the medical necessity and appropriateness of a health care service.\n\t\t\t“Health benefit plan” means a policy, contract, certificate, or agreement offered by a carrier to provide, deliver, arrange for, pay for, or reimburse any of the costs of services for the diagnosis, prevention, treatment, cure, or relief of a health condition, illness, injury, or disease and that provides coverage for prescription drugs. “Health benefit plan” includes any policy or plan providing health insurance coverage to state employees pursuant to § 2.2-2818.\n\t\t\t“Patient” means a policyholder, subscriber, participant, or other individual covered by a health benefit plan.\n\t\t\t“Provider” means a hospital, physician, or any type of provider licensed, certified, or authorized by statute to provide a covered service under the health benefit plan.\n\t\t\t“Step therapy exception” means overriding a step therapy protocol in favor of immediate coverage of the provider’s selected prescription drug provided that such drug is covered under the health benefit plan, which determination is based on a review of the patient’s or prescribing provider’s request for an override, along with supporting rationale and documentation.\n\t\t\t“Step therapy protocol” means a protocol setting the sequence in which prescription drugs for a specified medical condition and medically appropriate for a particular patient are covered under a health benefit plan.\n\t\t\t“Utilization review organization” means an entity that conducts utilization review, other than a carrier performing utilization review for its own health benefit plans.B\n\nCarriers or utilization review organizations that develop step therapy protocols for a health benefit plan shall ensure that those step therapy protocols:1\n\nAre developed and endorsed by a multidisciplinary panel of experts that manages conflicts of interest among the members of the writing and review groups by requiring members to disclose to the carrier any potential conflict of interest, including carriers and pharmaceutical manufacturers, and recuse themselves of voting if they have a conflict of interest;2\n\nAre based on peer-reviewed research and medical practice, and may also consider published clinical practice guidelines established for relevant patient subgroups in addition to or in the absence of peer-reviewed research; and3\n\nAre continually updated based on a review of new evidence, research, and newly developed treatments.C\n\nWhen establishing a step therapy protocol, a utilization review agent may also take into account the needs of atypical patient populations and diagnoses when establishing clinical review criteria.D\n\nThis section shall not be construed to require carriers to set up a new entity to develop clinical review criteria used for step therapy protocols.E\n\nWhen coverage of a prescription drug for the treatment of any medical condition is restricted for use by a carrier or utilization review organization through the use of a step therapy protocol, the patient and prescribing provider shall have access to a clear, readily accessible, and convenient process to request a step therapy exception. A carrier or utilization review organization may use its existing medical exceptions process to satisfy this requirement. The process shall be made easily accessible on the carrier’s or utilization review organization’s website.F\n\nA step therapy exception request shall be granted if the prescribing provider’s submitted justification and supporting clinical documentation, if needed, are determined to support the prescribing provider’s statement that:1\n\nThe required prescription drug is contraindicated;2\n\nThe required drug would be ineffective based on the known clinical characteristics of the patient and the known characteristics of the prescription drug regimen;3\n\nThe patient has tried the step therapy-required prescription drug while under their current or a previous health benefit plan, and such prescription drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event; or4\n\nThe patient is currently receiving a positive therapeutic outcome on a prescription drug recommended by his provider for the medical condition under consideration while on a current or the immediately preceding health benefit plan.G\n\nUpon the granting of a step therapy exception, the carrier or utilization review organization shall authorize coverage for the prescription drug prescribed by the patient’s treating provider, provided that the prescription drug is covered under the current health benefit plan.H\n\nThe carrier or utilization review organization shall respond to a step therapy exception request within 72 hours of receipt, including hours on weekends, that the request is approved, denied, or requires supplementation. In cases where exigent circumstances exist, a carrier or utilization review organization shall respond within 24 hours of receipt, including hours on weekends, that the request is approved, denied, or requires supplementation.I\n\nA patient may appeal any step therapy exception request denial made pursuant to this section under the health benefit plan’s existing appeal procedures.J\n\nDrug samples shall not be considered trial and failure of a preferred drug.K\n\nThis section shall not be construed to prevent a carrier or utilization review organization from requiring an enrollee to try an AB-rated generic equivalent or interchangeable biological product prior to providing coverage, or substitute a generic for a branded drug.L\n\nPursuant to the authority granted by § 38.2-223, the Commission may promulgate such rules and regulations as it may deem necessary to implement this section.M\n\nThis section shall apply to any health benefit plan delivered, issued for delivery, or renewed on or after January 1, 2020.","order_by":null,"text":{"0":{"id":257700,"text":"As used in this section:\n\t\t\t“Carrier” means any (i) insurer issuing individual or group accident and sickness insurance policies providing hospital, medical and surgical, or major medical coverage on an expense-incurred basis; (ii) corporation providing individual or group accident and sickness subscription contracts; or (iii) health maintenance organization providing a health care plan for health care services. “Carrier” includes any entity administering a policy or plan providing health insurance coverage to state employees pursuant to § 2.2-2818 but does not include any entity administering a policy or plan providing coverage pursuant to Title XVIII of the Social Security Act, 42 U.S.C. § 1395 et seq. (Medicare); Title XIX of the Social Security Act, 42 U.S.C. § 1396 et seq. (Medicaid); or Title XXI of the Social Security Act, 42 U.S.C. § 1397aa et seq. (CHIP).\n\t\t\t“Clinical practice guideline” means a systematically developed statement to assist decision making by providers about appropriate health care for a specific clinical circumstance or condition.\n\t\t\t“Clinical review criteria” means the written screening procedures, decision abstracts, clinical protocols, and practice guidelines used by a carrier, utilization review organization, or independent review organization to determine the medical necessity and appropriateness of a health care service.\n\t\t\t“Health benefit plan” means a policy, contract, certificate, or agreement offered by a carrier to provide, deliver, arrange for, pay for, or reimburse any of the costs of services for the diagnosis, prevention, treatment, cure, or relief of a health condition, illness, injury, or disease and that provides coverage for prescription drugs. “Health benefit plan” includes any policy or plan providing health insurance coverage to state employees pursuant to § 2.2-2818.\n\t\t\t“Patient” means a policyholder, subscriber, participant, or other individual covered by a health benefit plan.\n\t\t\t“Provider” means a hospital, physician, or any type of provider licensed, certified, or authorized by statute to provide a covered service under the health benefit plan.\n\t\t\t“Step therapy exception” means overriding a step therapy protocol in favor of immediate coverage of the provider’s selected prescription drug provided that such drug is covered under the health benefit plan, which determination is based on a review of the patient’s or prescribing provider’s request for an override, along with supporting rationale and documentation.\n\t\t\t“Step therapy protocol” means a protocol setting the sequence in which prescription drugs for a specified medical condition and medically appropriate for a particular patient are covered under a health benefit plan.\n\t\t\t“Utilization review organization” means an entity that conducts utilization review, other than a carrier performing utilization review for its own health benefit plans.","type":"section","prefixes":["A"],"prefix":"A","entire_prefix":"A","prefix_anchor":"A","level":1,"next_prefix":"B"},"1":{"id":257701,"text":"Carriers or utilization review organizations that develop step therapy protocols for a health benefit plan shall ensure that those step therapy protocols:","type":"section","prefixes":["B"],"prefix":"B","entire_prefix":"B","prefix_anchor":"B","level":1,"prior_prefix":"A","next_prefix":"B1"},"2":{"id":257702,"text":"Are developed and endorsed by a multidisciplinary panel of experts that manages conflicts of interest among the members of the writing and review groups by requiring members to disclose to the carrier any potential conflict of interest, including carriers and pharmaceutical manufacturers, and recuse themselves of voting if they have a conflict of interest;","type":"section","prefixes":["B","1"],"prefix":"1","entire_prefix":"B1","prefix_anchor":"B1","level":2,"prior_prefix":"B","next_prefix":"B2"},"3":{"id":257703,"text":"Are based on peer-reviewed research and medical practice, and may also consider published clinical practice guidelines established for relevant patient subgroups in addition to or in the absence of peer-reviewed research; and","type":"section","prefixes":["B","2"],"prefix":"2","entire_prefix":"B2","prefix_anchor":"B2","level":2,"prior_prefix":"B1","next_prefix":"B3"},"4":{"id":257704,"text":"Are continually updated based on a review of new evidence, research, and newly developed treatments.","type":"section","prefixes":["B","3"],"prefix":"3","entire_prefix":"B3","prefix_anchor":"B3","level":2,"prior_prefix":"B2","next_prefix":"C"},"5":{"id":257705,"text":"When establishing a step therapy protocol, a utilization review agent may also take into account the needs of atypical patient populations and diagnoses when establishing clinical review criteria.","type":"section","prefixes":["C"],"prefix":"C","entire_prefix":"C","prefix_anchor":"C","level":1,"prior_prefix":"B3","next_prefix":"D"},"6":{"id":257706,"text":"This section shall not be construed to require carriers to set up a new entity to develop clinical review criteria used for step therapy protocols.","type":"section","prefixes":["D"],"prefix":"D","entire_prefix":"D","prefix_anchor":"D","level":1,"prior_prefix":"C","next_prefix":"E"},"7":{"id":257707,"text":"When coverage of a prescription drug for the treatment of any medical condition is restricted for use by a carrier or utilization review organization through the use of a step therapy protocol, the patient and prescribing provider shall have access to a clear, readily accessible, and convenient process to request a step therapy exception. A carrier or utilization review organization may use its existing medical exceptions process to satisfy this requirement. The process shall be made easily accessible on the carrier’s or utilization review organization’s website.","type":"section","prefixes":["E"],"prefix":"E","entire_prefix":"E","prefix_anchor":"E","level":1,"prior_prefix":"D","next_prefix":"F"},"8":{"id":257708,"text":"A step therapy exception request shall be granted if the prescribing provider’s submitted justification and supporting clinical documentation, if needed, are determined to support the prescribing provider’s statement that:","type":"section","prefixes":["F"],"prefix":"F","entire_prefix":"F","prefix_anchor":"F","level":1,"prior_prefix":"E","next_prefix":"F1"},"9":{"id":257709,"text":"The required prescription drug is contraindicated;","type":"section","prefixes":["F","1"],"prefix":"1","entire_prefix":"F1","prefix_anchor":"F1","level":2,"prior_prefix":"F","next_prefix":"F2"},"10":{"id":257710,"text":"The required drug would be ineffective based on the known clinical characteristics of the patient and the known characteristics of the prescription drug regimen;","type":"section","prefixes":["F","2"],"prefix":"2","entire_prefix":"F2","prefix_anchor":"F2","level":2,"prior_prefix":"F1","next_prefix":"F3"},"11":{"id":257711,"text":"The patient has tried the step therapy-required prescription drug while under their current or a previous health benefit plan, and such prescription drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event; or","type":"section","prefixes":["F","3"],"prefix":"3","entire_prefix":"F3","prefix_anchor":"F3","level":2,"prior_prefix":"F2","next_prefix":"F4"},"12":{"id":257712,"text":"The patient is currently receiving a positive therapeutic outcome on a prescription drug recommended by his provider for the medical condition under consideration while on a current or the immediately preceding health benefit plan.","type":"section","prefixes":["F","4"],"prefix":"4","entire_prefix":"F4","prefix_anchor":"F4","level":2,"prior_prefix":"F3","next_prefix":"G"},"13":{"id":257713,"text":"Upon the granting of a step therapy exception, the carrier or utilization review organization shall authorize coverage for the prescription drug prescribed by the patient’s treating provider, provided that the prescription drug is covered under the current health benefit plan.","type":"section","prefixes":["G"],"prefix":"G","entire_prefix":"G","prefix_anchor":"G","level":1,"prior_prefix":"F4","next_prefix":"H"},"14":{"id":257714,"text":"The carrier or utilization review organization shall respond to a step therapy exception request within 72 hours of receipt, including hours on weekends, that the request is approved, denied, or requires supplementation. In cases where exigent circumstances exist, a carrier or utilization review organization shall respond within 24 hours of receipt, including hours on weekends, that the request is approved, denied, or requires supplementation.","type":"section","prefixes":["H"],"prefix":"H","entire_prefix":"H","prefix_anchor":"H","level":1,"prior_prefix":"G","next_prefix":"I"},"15":{"id":257715,"text":"A patient may appeal any step therapy exception request denial made pursuant to this section under the health benefit plan’s existing appeal procedures.","type":"section","prefixes":["I"],"prefix":"I","entire_prefix":"I","prefix_anchor":"I","level":1,"prior_prefix":"H","next_prefix":"J"},"16":{"id":257716,"text":"Drug samples shall not be considered trial and failure of a preferred drug.","type":"section","prefixes":["J"],"prefix":"J","entire_prefix":"J","prefix_anchor":"J","level":1,"prior_prefix":"I","next_prefix":"K"},"17":{"id":257717,"text":"This section shall not be construed to prevent a carrier or utilization review organization from requiring an enrollee to try an AB-rated generic equivalent or interchangeable biological product prior to providing coverage, or substitute a generic for a branded drug.","type":"section","prefixes":["K"],"prefix":"K","entire_prefix":"K","prefix_anchor":"K","level":1,"prior_prefix":"J","next_prefix":"L"},"18":{"id":257718,"text":"Pursuant to the authority granted by § 38.2-223, the Commission may promulgate such rules and regulations as it may deem necessary to implement this section.","type":"section","prefixes":["L"],"prefix":"L","entire_prefix":"L","prefix_anchor":"L","level":1,"prior_prefix":"K","next_prefix":"M"},"19":{"id":257719,"text":"This section shall apply to any health benefit plan delivered, issued for delivery, or renewed on or after January 1, 2020.","type":"section","prefixes":["M"],"prefix":"M","entire_prefix":"M","prefix_anchor":"M","level":1,"prior_prefix":"L"}},"ancestry":[{"id":12994,"edition_id":1,"name":"General Provisions","identifier":"1","label":"article","depth":3,"order_by":1,"parent_id":12993,"metadata":{},"date_created":"2026-06-26 03:44:07","date_modified":"2026-06-26 03:44:07","permalink":{"id":214889,"object_type":"structure","relational_id":12994,"identifier":"1","token":"38.2\/34\/1","url":"\/38.2\/34\/1\/","edition_id":1,"permalink":0,"preferred":1}},{"id":12993,"edition_id":1,"name":"Provisions Relating to Accident and Sickness Insurance","identifier":"34","label":"chapter","depth":2,"order_by":1,"parent_id":12698,"metadata":{},"date_created":"2026-06-26 03:44:07","date_modified":"2026-06-26 03:44:07","permalink":{"id":214887,"object_type":"structure","relational_id":12993,"identifier":"34","token":"38.2\/34","url":"\/38.2\/34\/","edition_id":1,"permalink":0,"preferred":1}},{"id":12698,"edition_id":1,"name":"Insurance","identifier":"38.2","label":"title","depth":1,"order_by":1,"parent_id":null,"metadata":{},"date_created":"2026-06-26 03:43:49","date_modified":"2026-06-26 03:43:49","permalink":{"id":210661,"object_type":"structure","relational_id":12698,"identifier":"38.2","token":"38.2","url":"\/38.2\/","edition_id":1,"permalink":0,"preferred":1}}],"structure_contents":[{"id":57593,"structure_id":12994,"section_number":"38.2-3400","catch_line":"Application of chapter","url":"\/38.2-3400\/","token":"38.2\/34\/1\/38.2-3400","metadata":false},{"id":72072,"structure_id":12994,"section_number":"38.2-3401","catch_line":"Forms of insurance authorized","url":"\/38.2-3401\/","token":"38.2\/34\/1\/38.2-3401","metadata":false},{"id":65240,"structure_id":12994,"section_number":"38.2-3402","catch_line":"Certification to accompany application","url":"\/38.2-3402\/","token":"38.2\/34\/1\/38.2-3402","metadata":false},{"id":83988,"structure_id":12994,"section_number":"38.2-3403","catch_line":"Fraudulent procurement of policy","url":"\/38.2-3403\/","token":"38.2\/34\/1\/38.2-3403","metadata":false},{"id":65279,"structure_id":12994,"section_number":"38.2-3404","catch_line":"Commission may establish rules and regulations for simplified and readable accident and sickness insurance policies","url":"\/38.2-3404\/","token":"38.2\/34\/1\/38.2-3404","metadata":false},{"id":62539,"structure_id":12994,"section_number":"38.2-3405","catch_line":"Certain subrogation provisions and limitations upon recovery in hospital, medical, etc., policies forbidden; limitations on disclosure of medical treatment options prohibited","url":"\/38.2-3405\/","token":"38.2\/34\/1\/38.2-3405","metadata":false},{"id":84136,"structure_id":12994,"section_number":"38.2-3405.1","catch_line":"Commonwealth's right to certain accident and sickness benefits","url":"\/38.2-3405.1\/","token":"38.2\/34\/1\/38.2-3405.1","metadata":false},{"id":70730,"structure_id":12994,"section_number":"38.2-3406","catch_line":"Accident and sickness benefits not subject to legal process","url":"\/38.2-3406\/","token":"38.2\/34\/1\/38.2-3406","metadata":false},{"id":84333,"structure_id":12994,"section_number":"38.2-3406.1","catch_line":"Application of requirements that policies offered by small employers include state-mandated health benefits","url":"\/38.2-3406.1\/","token":"38.2\/34\/1\/38.2-3406.1","metadata":false},{"id":67972,"structure_id":12994,"section_number":"38.2-3406.2","catch_line":"Capped benefits under insurance policies and contracts","url":"\/38.2-3406.2\/","token":"38.2\/34\/1\/38.2-3406.2","metadata":false},{"id":76321,"structure_id":12994,"section_number":"38.2-3407","catch_line":"Health benefit programs","url":"\/38.2-3407\/","token":"38.2\/34\/1\/38.2-3407","metadata":false},{"id":66921,"structure_id":12994,"section_number":"38.2-3407.1","catch_line":"Interest on accident and sickness claim proceeds","url":"\/38.2-3407.1\/","token":"38.2\/34\/1\/38.2-3407.1","metadata":false},{"id":58079,"structure_id":12994,"section_number":"38.2-3407.10","catch_line":"Health care provider panels","url":"\/38.2-3407.10\/","token":"38.2\/34\/1\/38.2-3407.10","metadata":false},{"id":66411,"structure_id":12994,"section_number":"38.2-3407.10:1","catch_line":"Processing of new provider applications and reimbursement for services rendered during pendency of a participating provider's credentialing application","url":"\/38.2-3407.10_1\/","token":"38.2\/34\/1\/38.2-3407.10_1","metadata":false},{"id":56463,"structure_id":12994,"section_number":"38.2-3407.10:2","catch_line":"Credentialing of private mental health agencies","url":"\/38.2-3407.10_2\/","token":"38.2\/34\/1\/38.2-3407.10_2","metadata":false},{"id":82372,"structure_id":12994,"section_number":"38.2-3407.11","catch_line":"Access to obstetrician-gynecologists","url":"\/38.2-3407.11\/","token":"38.2\/34\/1\/38.2-3407.11","metadata":false},{"id":70024,"structure_id":12994,"section_number":"38.2-3407.11:1","catch_line":"Access to specialists; standing referrals","url":"\/38.2-3407.11_1\/","token":"38.2\/34\/1\/38.2-3407.11_1","metadata":false},{"id":71393,"structure_id":12994,"section_number":"38.2-3407.11:2","catch_line":"Standing referral for cancer patients","url":"\/38.2-3407.11_2\/","token":"38.2\/34\/1\/38.2-3407.11_2","metadata":false},{"id":72434,"structure_id":12994,"section_number":"38.2-3407.11:3","catch_line":"Breast cancer underwriting and preexisting condition restrictions","url":"\/38.2-3407.11_3\/","token":"38.2\/34\/1\/38.2-3407.11_3","metadata":false},{"id":64402,"structure_id":12994,"section_number":"38.2-3407.11:4","catch_line":"Disability arising out of childbirth; minimum benefit","url":"\/38.2-3407.11_4\/","token":"38.2\/34\/1\/38.2-3407.11_4","metadata":false},{"id":66706,"structure_id":12994,"section_number":"38.2-3407.11:5","catch_line":"Interhospital transfer for newborn or mother; prior authorization prohibited","url":"\/38.2-3407.11_5\/","token":"38.2\/34\/1\/38.2-3407.11_5","metadata":false},{"id":68442,"structure_id":12994,"section_number":"38.2-3407.12","catch_line":"Patient optional point-of-service benefit","url":"\/38.2-3407.12\/","token":"38.2\/34\/1\/38.2-3407.12","metadata":false},{"id":81634,"structure_id":12994,"section_number":"38.2-3407.13","catch_line":"Refusal to accept assignments prohibited; dentists and oral surgeons","url":"\/38.2-3407.13\/","token":"38.2\/34\/1\/38.2-3407.13","metadata":false},{"id":79541,"structure_id":12994,"section_number":"38.2-3407.13:1","catch_line":"Coordination of benefits; notice of priority of coverage","url":"\/38.2-3407.13_1\/","token":"38.2\/34\/1\/38.2-3407.13_1","metadata":false},{"id":87429,"structure_id":12994,"section_number":"38.2-3407.13:2","catch_line":"Claims paid to insureds for services from nonparticipating physicians","url":"\/38.2-3407.13_2\/","token":"38.2\/34\/1\/38.2-3407.13_2","metadata":false},{"id":60288,"structure_id":12994,"section_number":"38.2-3407.14","catch_line":"Notice of premium or deductible increases","url":"\/38.2-3407.14\/","token":"38.2\/34\/1\/38.2-3407.14","metadata":false},{"id":82945,"structure_id":12994,"section_number":"38.2-3407.14:1","catch_line":"Standard of clinical evidence for decisions on coverage for proton radiation therapy","url":"\/38.2-3407.14_1\/","token":"38.2\/34\/1\/38.2-3407.14_1","metadata":false},{"id":71060,"structure_id":12994,"section_number":"38.2-3407.15","catch_line":"Ethics and fairness in carrier business practices","url":"\/38.2-3407.15\/","token":"38.2\/34\/1\/38.2-3407.15","metadata":false},{"id":79973,"structure_id":12994,"section_number":"38.2-3407.15:1","catch_line":"Carrier contracts with pharmacy providers; required provisions; limit on termination or nonrenewal","url":"\/38.2-3407.15_1\/","token":"38.2\/34\/1\/38.2-3407.15_1","metadata":false},{"id":81930,"structure_id":12994,"section_number":"38.2-3407.15:2","catch_line":"(Effective January 1, 2027) Carrier contracts; required provisions regarding prior authorization for drug benefits","url":"\/38.2-3407.15_2\/","token":"38.2\/34\/1\/38.2-3407.15_2","metadata":false},{"id":77493,"structure_id":12994,"section_number":"38.2-3407.15:3","catch_line":"Carrier and intermediary contracts with pharmacy providers; disclosure and updating of maximum allowable cost of drugs; limit on termination or nonrenewal","url":"\/38.2-3407.15_3\/","token":"38.2\/34\/1\/38.2-3407.15_3","metadata":false},{"id":73491,"structure_id":12994,"section_number":"38.2-3407.15:4","catch_line":"Limit on copayment for prescription drugs; permitted disclosures","url":"\/38.2-3407.15_4\/","token":"38.2\/34\/1\/38.2-3407.15_4","metadata":false},{"id":57527,"structure_id":12994,"section_number":"38.2-3407.15:5","catch_line":"Limit on cost-sharing payments for prescription insulin drugs","url":"\/38.2-3407.15_5\/","token":"38.2\/34\/1\/38.2-3407.15_5","metadata":false},{"id":80337,"structure_id":12994,"section_number":"38.2-3407.15:6","catch_line":"Prescription drug price transparency","url":"\/38.2-3407.15_6\/","token":"38.2\/34\/1\/38.2-3407.15_6","metadata":false},{"id":87317,"structure_id":12994,"section_number":"38.2-3407.15:7","catch_line":"Carrier provision of certain information","url":"\/38.2-3407.15_7\/","token":"38.2\/34\/1\/38.2-3407.15_7","metadata":false},{"id":82040,"structure_id":12994,"section_number":"38.2-3407.15:8","catch_line":"(Effective January 1, 2027) Carrier contracts; required provisions regarding prior authorization for health care services","url":"\/38.2-3407.15_8\/","token":"38.2\/34\/1\/38.2-3407.15_8","metadata":false},{"id":76440,"structure_id":12994,"section_number":"38.2-3407.16","catch_line":"Requirements for obstetrical care","url":"\/38.2-3407.16\/","token":"38.2\/34\/1\/38.2-3407.16","metadata":false},{"id":64799,"structure_id":12994,"section_number":"38.2-3407.17","catch_line":"Payment for services by dentists and oral surgeons","url":"\/38.2-3407.17\/","token":"38.2\/34\/1\/38.2-3407.17","metadata":false},{"id":55530,"structure_id":12994,"section_number":"38.2-3407.17:1","catch_line":"Payment and reimbursement practices for dental services; network access","url":"\/38.2-3407.17_1\/","token":"38.2\/34\/1\/38.2-3407.17_1","metadata":false},{"id":81770,"structure_id":12994,"section_number":"38.2-3407.18","catch_line":"Requirements for orally administered cancer chemotherapy drugs","url":"\/38.2-3407.18\/","token":"38.2\/34\/1\/38.2-3407.18","metadata":false},{"id":83502,"structure_id":12994,"section_number":"38.2-3407.19","catch_line":"Payment for services by optometrists and ophthalmologists","url":"\/38.2-3407.19\/","token":"38.2\/34\/1\/38.2-3407.19","metadata":false},{"id":77646,"structure_id":12994,"section_number":"38.2-3407.2","catch_line":"Coverage for medical child support","url":"\/38.2-3407.2\/","token":"38.2\/34\/1\/38.2-3407.2","metadata":false},{"id":73127,"structure_id":12994,"section_number":"38.2-3407.20","catch_line":"Calculation of enrollee's contribution to out-of-pocket maximum or cost-sharing requirement","url":"\/38.2-3407.20\/","token":"38.2\/34\/1\/38.2-3407.20","metadata":false},{"id":57407,"structure_id":12994,"section_number":"38.2-3407.21","catch_line":"Short-term limited-duration medical plans","url":"\/38.2-3407.21\/","token":"38.2\/34\/1\/38.2-3407.21","metadata":false},{"id":85964,"structure_id":12994,"section_number":"38.2-3407.22","catch_line":"Option for rebates to enrollees; protected information","url":"\/38.2-3407.22\/","token":"38.2\/34\/1\/38.2-3407.22","metadata":false},{"id":81846,"structure_id":12994,"section_number":"38.2-3407.3","catch_line":"Calculation of cost-sharing provisions","url":"\/38.2-3407.3\/","token":"38.2\/34\/1\/38.2-3407.3","metadata":false},{"id":62583,"structure_id":12994,"section_number":"38.2-3407.3:1","catch_line":"Premium payment arrearages; order of crediting payments","url":"\/38.2-3407.3_1\/","token":"38.2\/34\/1\/38.2-3407.3_1","metadata":false},{"id":78457,"structure_id":12994,"section_number":"38.2-3407.4","catch_line":"Explanation of benefits","url":"\/38.2-3407.4\/","token":"38.2\/34\/1\/38.2-3407.4","metadata":false},{"id":72294,"structure_id":12994,"section_number":"38.2-3407.4:1","catch_line":"Repealed","url":"\/38.2-3407.4_1\/","token":"38.2\/34\/1\/38.2-3407.4_1","metadata":false},{"id":57129,"structure_id":12994,"section_number":"38.2-3407.4:2","catch_line":"Requirements for prescription benefit cards","url":"\/38.2-3407.4_2\/","token":"38.2\/34\/1\/38.2-3407.4_2","metadata":false},{"id":62057,"structure_id":12994,"section_number":"38.2-3407.5","catch_line":"Denial of benefits for certain prescription drugs prohibited","url":"\/38.2-3407.5\/","token":"38.2\/34\/1\/38.2-3407.5","metadata":false},{"id":54072,"structure_id":12994,"section_number":"38.2-3407.5:1","catch_line":"Coverage for prescription contraceptives","url":"\/38.2-3407.5_1\/","token":"38.2\/34\/1\/38.2-3407.5_1","metadata":false},{"id":79611,"structure_id":12994,"section_number":"38.2-3407.5:2","catch_line":"Reimbursements for dispensing hormonal contraceptives","url":"\/38.2-3407.5_2\/","token":"38.2\/34\/1\/38.2-3407.5_2","metadata":false},{"id":83778,"structure_id":12994,"section_number":"38.2-3407.6","catch_line":"Exclusion of podiatrist not permitted under certain circumstances","url":"\/38.2-3407.6\/","token":"38.2\/34\/1\/38.2-3407.6","metadata":false},{"id":74649,"structure_id":12994,"section_number":"38.2-3407.6:1","catch_line":"Denial of benefits for certain prescription drugs prohibited","url":"\/38.2-3407.6_1\/","token":"38.2\/34\/1\/38.2-3407.6_1","metadata":false},{"id":72641,"structure_id":12994,"section_number":"38.2-3407.7","catch_line":"Pharmacies; freedom of choice","url":"\/38.2-3407.7\/","token":"38.2\/34\/1\/38.2-3407.7","metadata":false},{"id":73400,"structure_id":12994,"section_number":"38.2-3407.8","catch_line":"Repealed","url":"\/38.2-3407.8\/","token":"38.2\/34\/1\/38.2-3407.8","metadata":false},{"id":72540,"structure_id":12994,"section_number":"38.2-3407.9","catch_line":"Reimbursement for emergency medical services vehicle transportation services","url":"\/38.2-3407.9\/","token":"38.2\/34\/1\/38.2-3407.9","metadata":false},{"id":62232,"structure_id":12994,"section_number":"38.2-3407.9:01","catch_line":"Prescription drug formularies","url":"\/38.2-3407.9_01\/","token":"38.2\/34\/1\/38.2-3407.9_01","metadata":false},{"id":62074,"structure_id":12994,"section_number":"38.2-3407.9:02","catch_line":"Requirement for prescription drug coverage","url":"\/38.2-3407.9_02\/","token":"38.2\/34\/1\/38.2-3407.9_02","metadata":false},{"id":68601,"structure_id":12994,"section_number":"38.2-3407.9:03","catch_line":"Payment of clean claims to administrators of pharmacy benefits","url":"\/38.2-3407.9_03\/","token":"38.2\/34\/1\/38.2-3407.9_03","metadata":false},{"id":56568,"structure_id":12994,"section_number":"38.2-3407.9:04","catch_line":"Medication synchronization","url":"\/38.2-3407.9_04\/","token":"38.2\/34\/1\/38.2-3407.9_04","metadata":false},{"id":71499,"structure_id":12994,"section_number":"38.2-3407.9:05","catch_line":"Step therapy protocols","url":"\/38.2-3407.9_05\/","token":"38.2\/34\/1\/38.2-3407.9_05","metadata":false}],"previous_section":{"id":56568,"structure_id":12994,"section_number":"38.2-3407.9:04","catch_line":"Medication synchronization","url":"\/38.2-3407.9_04\/","token":"38.2\/34\/1\/38.2-3407.9_04","metadata":false},"metadata":false,"official_url":"https:\/\/law.lis.virginia.gov\/vacode\/38.2-3407.9:05\/","history_text":"

This law was first created in 2019. The record of its establishment is cataloged in chapter 337<\/a> of that year\u2019s edition of \u201cActs of Assembly,\u201d the annual state publication listing all changes made to the Code of Virginia in that year.<\/p>","references":false,"refers_to":[{"id":68317,"section_number":"2.2-2818","catch_line":"Health and related insurance for state employees","order_by":null,"url":"\/2.2-2818\/"},{"id":87496,"section_number":"38.2-223","catch_line":"Rules and regulations; orders","order_by":null,"url":"\/38.2-223\/"}],"permalink":{"id":215139,"object_type":"law","relational_id":71499,"identifier":"38.2-3407.9:05","token":"38.2\/34\/1\/38.2-3407.9_05","url":"\/38.2-3407.9_05\/","edition_id":1,"permalink":0,"preferred":1},"url":"\/38.2-3407.9_05\/","token":"38.2\/34\/1\/38.2-3407.9_05","dublin_core":{"Title":"Step therapy protocols","Type":"Text","Format":"text\/html","Identifier":"\u00a7 38.2-3407.9:05","Relation":"Code of Virginia"},"html":"\n\t\t\t\t\t\t

A.<\/span> As used in this section:\n\t\t\t“Carrier<\/span>” means any (i) insurer<\/span> issuing individual or group accident and sickness insurance policies<\/span> providing hospital, medical and surgical, or major medical coverage on an expense-incurred basis; (ii) corporation providing individual or group accident and sickness subscription contracts<\/span>; or (iii) health maintenance organization providing a health care plan for health care services. “Carrier<\/span>” includes any entity administering a policy or plan providing health insurance coverage to state<\/span> employees pursuant to § 2.2-2818<\/a> but does not include any entity administering a policy or plan providing coverage pursuant to Title XVIII of the Social Security Act, 42 U.S.C. § 1395 et seq. (Medicare<\/span>); Title XIX of the Social Security Act, 42 U.S.C. § 1396 et seq. (Medicaid); or Title XXI of the Social Security Act, 42 U.S.C. § 1397aa et seq. (CHIP).\n\t\t\t“Clinical practice guideline<\/span>” means a systematically developed statement to assist decision making by providers<\/span> about appropriate health care for a specific clinical circumstance or condition.\n\t\t\t“Clinical review criteria<\/span>” means the written screening procedures, decision abstracts, clinical protocols, and practice guidelines used by a carrier<\/span>, utilization review organization<\/span>, or independent review organization to determine the medical necessity and appropriateness of a health care service.\n\t\t\t“Health benefit plan<\/span>” means a policy, contract<\/span>, certificate, or agreement offered by a carrier<\/span> to provide, deliver, arrange for, pay for, or reimburse any of the costs of services for the diagnosis, prevention, treatment, cure, or relief of a health condition, illness, injury, or disease and that provides coverage for prescription drugs. “Health benefit plan<\/span>” includes any policy or plan providing health insurance coverage to state<\/span> employees pursuant to § 2.2-2818<\/a>.\n\t\t\t“Patient<\/span>” means a policyholder, subscriber, participant, or other individual covered by a health benefit plan<\/span>.\n\t\t\t“Provider<\/span>” means a hospital, physician, or any type of provider<\/span> licensed, certified, or authorized by statute<\/span> to provide a covered service under the health benefit plan<\/span>.\n\t\t\t“Step therapy exception<\/span>” means overriding a step therapy protocol<\/span> in favor of immediate coverage of the provider<\/span>’s selected prescription drug provided that such drug is covered under the health benefit plan<\/span>, which determination is based on a review of the patient<\/span>’s or prescribing provider<\/span>’s request for an override, along with supporting rationale and documentation.\n\t\t\t“Step therapy protocol<\/span>” means a protocol setting the sequence in which prescription drugs for a specified medical condition and medically appropriate for a particular patient<\/span> are covered under a health benefit plan<\/span>.\n\t\t\t“Utilization review organization<\/span>” means an entity that conducts utilization review, other than a carrier<\/span> performing utilization review for its own health benefit plans<\/span>. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

B.<\/span> Carriers<\/span> or utilization review organizations<\/span> that develop step therapy protocols<\/span> for a health benefit plan<\/span> shall ensure that those step therapy protocols<\/span>: <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

1.<\/span> Are developed and endorsed by a multidisciplinary panel<\/span> of experts that manages conflicts of interest among the members of the writing and review groups by requiring members to disclose to the carrier<\/span> any potential conflict of interest<\/span>, including carriers<\/span> and pharmaceutical manufacturers, and recuse<\/span> themselves of voting if they have a conflict of interest<\/span>; <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

2.<\/span> Are based on peer-reviewed research and medical practice, and may also consider published clinical practice guidelines<\/span> established for relevant patient<\/span> subgroups in addition to or in the absence of peer-reviewed research; and <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

3.<\/span> Are continually updated based on a review of new evidence<\/span>, research, and newly developed treatments. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

C.<\/span> When establishing a step therapy protocol<\/span>, a utilization review agent may also take into account the needs of atypical patient<\/span> populations and diagnoses when establishing clinical review criteria<\/span>. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

D.<\/span> This section shall not be construed to require carriers<\/span> to set up a new entity to develop clinical review criteria<\/span> used for step therapy protocols<\/span>. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

E.<\/span> When coverage of a prescription drug for the treatment of any medical condition is restricted for use by a carrier<\/span> or utilization review organization<\/span> through the use of a step therapy protocol<\/span>, the patient<\/span> and prescribing provider<\/span> shall have access to a clear, readily accessible, and convenient process to request a step therapy exception<\/span>. A carrier<\/span> or utilization review organization<\/span> may use its existing medical exceptions process to satisfy this requirement. The process shall be made easily accessible on the carrier<\/span>’s or utilization review organization<\/span>’s website. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

F.<\/span> A step therapy exception<\/span> request shall be granted if the prescribing provider<\/span>’s submitted justification and supporting clinical documentation, if needed, are determined to support the prescribing provider<\/span>’s statement that: <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

1.<\/span> The required prescription drug is contraindicated; <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

2.<\/span> The required drug would be ineffective based on the known clinical characteristics of the patient<\/span> and the known characteristics of the prescription drug regimen; <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

3.<\/span> The patient<\/span> has tried the step therapy-required prescription drug while under their current or a previous health benefit plan<\/span>, and such prescription drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event; or <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

4.<\/span> The patient<\/span> is currently receiving a positive therapeutic outcome on a prescription drug recommended by his provider<\/span> for the medical condition under consideration while on a current or the immediately preceding health benefit plan<\/span>. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

G.<\/span> Upon the granting of a step therapy exception<\/span>, the carrier<\/span> or utilization review organization<\/span> shall authorize coverage for the prescription drug prescribed by the patient<\/span>’s treating provider<\/span>, provided that the prescription drug is covered under the current health benefit plan<\/span>. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

H.<\/span> The carrier<\/span> or utilization review organization<\/span> shall respond to a step therapy exception<\/span> request within 72 hours of receipt, including hours on weekends, that the request is approved, denied, or requires supplementation. In cases where exigent circumstances exist, a carrier<\/span> or utilization review organization<\/span> shall respond within 24 hours of receipt, including hours on weekends, that the request is approved, denied, or requires supplementation. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

I.<\/span> A patient<\/span> may appeal<\/span> any step therapy exception<\/span> request denial made pursuant to this section under the health benefit plan<\/span>’s existing appeal<\/span> procedures. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

J.<\/span> Drug samples shall not be considered trial<\/span> and failure of a preferred drug. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

K.<\/span> This section shall not be construed to prevent a carrier<\/span> or utilization review organization<\/span> from requiring an enrollee to try an AB-rated generic equivalent or interchangeable biological product prior to providing coverage, or substitute a generic for a branded drug. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

L.<\/span> Pursuant to the authority granted by § 38.2-223<\/a>, the Commission<\/span> may promulgate such rules and regulations as it may deem necessary to implement this section. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

M.<\/span> This section shall apply to any health benefit plan<\/span> delivered, issued for delivery, or renewed on or after January 1, 2020. <\/i><\/a><\/p><\/section>","plain_text":" CODE OF VIRGINIA\n\nSTEP THERAPY PROTOCOLS (\u00a7 38.2-3407.9:05)\n\nA. As used in this section:\n\t\t\t“Carrier” means any (i) insurer issuing individual or group\naccident and sickness insurance policies providing hospital, medical and\nsurgical, or major medical coverage on an expense-incurred basis; (ii)\ncorporation providing individual or group accident and sickness subscription\ncontracts; or (iii) health maintenance organization providing a health care plan\nfor health care services. “Carrier” includes any entity\nadministering a policy or plan providing health insurance coverage to state\nemployees pursuant to § 2.2-2818 but does not include any entity\nadministering a policy or plan providing coverage pursuant to Title XVIII of the\nSocial Security Act, 42 U.S.C. § 1395 et seq. (Medicare); Title XIX of the\nSocial Security Act, 42 U.S.C. § 1396 et seq. (Medicaid); or Title XXI of\nthe Social Security Act, 42 U.S.C. § 1397aa et seq. (CHIP).\n\t\t\t“Clinical practice guideline” means a systematically developed\nstatement to assist decision making by providers about appropriate health care\nfor a specific clinical circumstance or condition.\n\t\t\t“Clinical review criteria” means the written screening\nprocedures, decision abstracts, clinical protocols, and practice guidelines used\nby a carrier, utilization review organization, or independent review\norganization to determine the medical necessity and appropriateness of a health\ncare service.\n\t\t\t“Health benefit plan” means a policy, contract, certificate, or\nagreement offered by a carrier to provide, deliver, arrange for, pay for, or\nreimburse any of the costs of services for the diagnosis, prevention, treatment,\ncure, or relief of a health condition, illness, injury, or disease and that\nprovides coverage for prescription drugs. “Health benefit plan”\nincludes any policy or plan providing health insurance coverage to state\nemployees pursuant to § 2.2-2818.\n\t\t\t“Patient” means a policyholder, subscriber, participant, or other\nindividual covered by a health benefit plan.\n\t\t\t“Provider” means a hospital, physician, or any type of provider\nlicensed, certified, or authorized by statute to provide a covered service under\nthe health benefit plan.\n\t\t\t“Step therapy exception” means overriding a step therapy protocol\nin favor of immediate coverage of the provider’s selected prescription\ndrug provided that such drug is covered under the health benefit plan, which\ndetermination is based on a review of the patient’s or prescribing\nprovider’s request for an override, along with supporting rationale and\ndocumentation.\n\t\t\t“Step therapy protocol” means a protocol setting the sequence in\nwhich prescription drugs for a specified medical condition and medically\nappropriate for a particular patient are covered under a health benefit plan.\n\t\t\t“Utilization review organization” means an entity that conducts\nutilization review, other than a carrier performing utilization review for its\nown health benefit plans.\n\nB. Carriers or utilization review organizations that develop step therapy\nprotocols for a health benefit plan shall ensure that those step therapy\nprotocols:\n\n 1. Are developed and endorsed by a multidisciplinary panel of experts that\n manages conflicts of interest among the members of the writing and review\n groups by requiring members to disclose to the carrier any potential conflict\n of interest, including carriers and pharmaceutical manufacturers, and recuse\n themselves of voting if they have a conflict of interest;\n\n 2. Are based on peer-reviewed research and medical practice, and may also\n consider published clinical practice guidelines established for relevant\n patient subgroups in addition to or in the absence of peer-reviewed research;\n and\n\n 3. Are continually updated based on a review of new evidence, research, and\n newly developed treatments.\n\nC. When establishing a step therapy protocol, a utilization review agent may\nalso take into account the needs of atypical patient populations and diagnoses\nwhen establishing clinical review criteria.\n\nD. This section shall not be construed to require carriers to set up a new\nentity to develop clinical review criteria used for step therapy protocols.\n\nE. When coverage of a prescription drug for the treatment of any medical\ncondition is restricted for use by a carrier or utilization review organization\nthrough the use of a step therapy protocol, the patient and prescribing provider\nshall have access to a clear, readily accessible, and convenient process to\nrequest a step therapy exception. A carrier or utilization review organization\nmay use its existing medical exceptions process to satisfy this requirement. The\nprocess shall be made easily accessible on the carrier’s or utilization\nreview organization’s website.\n\nF. A step therapy exception request shall be granted if the prescribing\nprovider’s submitted justification and supporting clinical documentation,\nif needed, are determined to support the prescribing provider’s statement\nthat:\n\n 1. The required prescription drug is contraindicated;\n\n 2. The required drug would be ineffective based on the known clinical\n characteristics of the patient and the known characteristics of the\n prescription drug regimen;\n\n 3. The patient has tried the step therapy-required prescription drug while\n under their current or a previous health benefit plan, and such prescription\n drug was discontinued due to lack of efficacy or effectiveness, diminished\n effect, or an adverse event; or\n\n 4. The patient is currently receiving a positive therapeutic outcome on a\n prescription drug recommended by his provider for the medical condition under\n consideration while on a current or the immediately preceding health benefit\n plan.\n\nG. Upon the granting of a step therapy exception, the carrier or utilization\nreview organization shall authorize coverage for the prescription drug\nprescribed by the patient’s treating provider, provided that the\nprescription drug is covered under the current health benefit plan.\n\nH. The carrier or utilization review organization shall respond to a step\ntherapy exception request within 72 hours of receipt, including hours on\nweekends, that the request is approved, denied, or requires supplementation. In\ncases where exigent circumstances exist, a carrier or utilization review\norganization shall respond within 24 hours of receipt, including hours on\nweekends, that the request is approved, denied, or requires supplementation.\n\nI. A patient may appeal any step therapy exception request denial made pursuant\nto this section under the health benefit plan’s existing appeal\nprocedures.\n\nJ. Drug samples shall not be considered trial and failure of a preferred drug.\n\nK. This section shall not be construed to prevent a carrier or utilization\nreview organization from requiring an enrollee to try an AB-rated generic\nequivalent or interchangeable biological product prior to providing coverage, or\nsubstitute a generic for a branded drug.\n\nL. Pursuant to the authority granted by § 38.2-223, the Commission may\npromulgate such rules and regulations as it may deem necessary to implement this\nsection.\n\nM. This section shall apply to any health benefit plan delivered, issued for\ndelivery, or renewed on or after January 1, 2020.\n\nHISTORY: 2019, c. 337.","edition":{"id":1,"name":"2025","slug":"2025","date_created":"2026-06-21 22:39:22","date_modified":"2026-06-21 22:39:22","current":1,"order_by":1,"last_import":null}}